AVTX Avalo Therapeutics, Inc.

NASDAQ
$19.59

Avalo Therapeutics, Inc. (AVTX) is expected to report earnings on November 5, 2026, before the market open. The consensus earnings estimate is a loss of $0.63 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +9.6% since its last earnings release on August 6, 2026.

Avalo Therapeutics Missed Consensus Estimates
Thursday, August 6, 2026 · 7:00 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 5
Thursday · 7:00 AM ET
Earnings Whisper
-
vs ($0.63)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $19.24

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Avalo Therapeutics, Inc.

Avalo Therapeutics Inc. is a clinical-stage precision medicine company which discovers, develops and commercializes targeted therapeutics for patients with significant unmet clinical need in immunology, immuno-oncology and rare genetic diseases. Avalo Therapeutics Inc., formerly known as Cerecor, is based in WAYNE, Pa.

Sector

Healthcare

Industry

Biotechnology